FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

Full description

Bibliographic Details
Main Authors: Ye Wang, Zhuang Tong, Wenhua Zhang, Weizhen Zhang, Anton Buzdin, Xiaofeng Mu, Qing Yan, Xiaowen Zhao, Hui-Hua Chang, Mark Duhon, Xin Zhou, Gexin Zhao, Hong Chen, Xinmin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
predictive biomarkers
PD-1
TMB
FDA-approved biomarkers
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.683419/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.683419/full

Similar Items